Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGX202 in Advanced Retinitis Pigmentosa
NCT07847723Phase 1Not yet recruiting
- Sponsor
- UgeneX Therapeutics
- Start
- Sep 2026
- Primary completion
- Feb 2029
01
Overview
Phase 1, open-label, single-arm trial of UGX-202 in retinitis pigmentosa (RP), sponsored by UgeneX Therapeutics. Primary endpoint: Safety and tolerability at 52 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
UGX-202
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT07847723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847723.